No Comments! Be The First!
Apogenix Obtains Roughly $3.66M to Further Cancer and Inflammatory …
Posted By
German biopharmaceutical Apogenix was awarded €2.6 million (about $3.66 million) in federal grants to support the development of an IL-4 inhibitor against chemotherapy- and radiotherapy-resistant cancers as well as CD95 ligand (CD95L) inhibitors …
SOURCE FOCUS: More Articles From genengnews.com
Protel Associates Limited (Protel) (Taunton, United Kingdom) are proud to announce that we have entered into a strategic business allia …
HOUSTON – (May 13, 2009) Arthropods and mollusks are Nature’s true bluebloods thanks to hemocyanin, an oxygen-carrying large protein co …
JDA ® Software Group, Inc. ( NASDAQ: JDAS ) today announced that Bayer Santé Familiale , the French operational division of Bayer Con …
Over the past decade various pieces of the puzzle how signal transmission controls immunity have been coming together. Now, in Cell an …
More from Country Code Domains
Jul 31st, 2009